Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G A Opler

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Environmental Health Perspectives|September 6, 2005
Fetal environment and schizophreniaMark G A Opler, Ezra S Susser
Innovations in Clinical Neuroscience|February 8, 2018
Positive and Negative Syndrome Scale (PANSS) Training: Challenges, Solutions, and Future DirectionsMark G A Opler, Christian Yavorsky, David G Daniel
Schizophrenia Research|March 6, 2007
PANSS rater training using Internet and videoconference: results from a pilot studyKenneth A Kobak, Mark G A Opler, Nina Engelhardt
Innovations in Clinical Neuroscience|February 8, 2018
Bridging the Measurement Gap Between Research and Clinical Care in Schizophrenia: Positive and Negative Syndrome Scale-6 (PANSS-6) and Other Assessments Based on the Simplified Negative and Positive Symptoms Interview (SNAPSI)Søren D Østergaard, Mark G A Opler, Christoph U Correll
CNS Spectrums|January 27, 2015
Ameliorating treatment-refractory depression with intranasal ketamine: potential NMDA receptor actions in the pain circuitry representing mental anguishLewis A Opler, Mark G A Opler, Amy F T Arnsten
BMC Psychiatry|July 26, 2007
Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findingsMark G A Opler, Lawrence H Yang, Sue Caleo, et al.
Innovations in Clinical Neuroscience|March 18, 2024
Functioning and Cognition in Patients with Schizophrenia After Initiating Treatment with Aripiprazole Lauroxil: Secondary Outcomes and Post Hoc AnalysisMark G A Opler, Amy Claxton, James McGrory, et al.
Expert Review of Neurotherapeutics|October 8, 2010
Brain tumor location and psychiatric symptoms: is there any association? A meta-analysis of published case studiesSubramoniam Madhusoodanan, Mark G A Opler, Despina Moise, et al.
Schizophrenia Research|February 16, 2010
Time-to-pregnancy and risk of schizophreniaMark G A Opler, Susan Harlap, Katherine Ornstein, et al.
Environmental Health Perspectives|April 6, 2004
Prenatal lead exposure, delta-aminolevulinic acid, and schizophreniaMark G A Opler, Alan S Brown, Joseph Graziano, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Environmental Health Perspectives|September 6, 2005
Fetal environment and schizophreniaMark G A Opler, Ezra S Susser
Innovations in Clinical Neuroscience|February 8, 2018
Positive and Negative Syndrome Scale (PANSS) Training: Challenges, Solutions, and Future DirectionsMark G A Opler, Christian Yavorsky, David G Daniel
Schizophrenia Research|March 6, 2007
PANSS rater training using Internet and videoconference: results from a pilot studyKenneth A Kobak, Mark G A Opler, Nina Engelhardt
Innovations in Clinical Neuroscience|February 8, 2018
Bridging the Measurement Gap Between Research and Clinical Care in Schizophrenia: Positive and Negative Syndrome Scale-6 (PANSS-6) and Other Assessments Based on the Simplified Negative and Positive Symptoms Interview (SNAPSI)Søren D Østergaard, Mark G A Opler, Christoph U Correll
CNS Spectrums|January 27, 2015
Ameliorating treatment-refractory depression with intranasal ketamine: potential NMDA receptor actions in the pain circuitry representing mental anguishLewis A Opler, Mark G A Opler, Amy F T Arnsten
BMC Psychiatry|July 26, 2007
Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findingsMark G A Opler, Lawrence H Yang, Sue Caleo, et al.
Innovations in Clinical Neuroscience|March 18, 2024
Functioning and Cognition in Patients with Schizophrenia After Initiating Treatment with Aripiprazole Lauroxil: Secondary Outcomes and Post Hoc AnalysisMark G A Opler, Amy Claxton, James McGrory, et al.
Expert Review of Neurotherapeutics|October 8, 2010
Brain tumor location and psychiatric symptoms: is there any association? A meta-analysis of published case studiesSubramoniam Madhusoodanan, Mark G A Opler, Despina Moise, et al.
Schizophrenia Research|February 16, 2010
Time-to-pregnancy and risk of schizophreniaMark G A Opler, Susan Harlap, Katherine Ornstein, et al.
Environmental Health Perspectives|April 6, 2004
Prenatal lead exposure, delta-aminolevulinic acid, and schizophreniaMark G A Opler, Alan S Brown, Joseph Graziano, et al.
Pageof 2